著者

采見 憲男 武田 節夫 北里 健二 梶原 大義 藤井 節郎

出版者

公益社団法人 日本化学療法学会

雑誌

CHEMOTHERAPY (ISSN:00093165)

巻号頁・発行日

vol.26, no.2, pp.200-208, 1978-03-25 (Released:2011-03-08)

参考文献数

13

---

The antitumor activity of 1, 3-Bis (tetrahydro-2-furanyl) -5-fluoro-2, 4-pyrimidinedione (FD-1) was compared with that of 1- (2-Tetrahydrofuryl) -5-fluorouracil (FT) or 5-Fluorouracil (5-FU) in a number of tumor systems.FD-1 had significant activity against the solid forms but not the ascitic forms, and it produced a greater inhibition in tumor growth than FT. On AH 130 solid form, the therapeutic index (LD50/ED50) of FD-1 and FT were respectively 18. 3 and 10.6.FD-1 was evaluated against the ip and sc implanted L 1210 leukemia by single, intermittent or daily administration. FD-1 retained some degree of antileukemic activity against the ic implanted L 1210.No significant difference in antitumor activity was observed between the R and S isomers or the racemic mixture (FD-1).A higher activity of FD-1 compared to FT was possibly due to the increased 5-FU level in tumor through its metabolite, 3- (tetrahydro-2-furanyl) -5-fluoro-2, 4-pyrimidinedione (3-FT).